Amphastar Secures FDA Nod For Iron Sucrose Injection, Analysts Eye Major Sales Momentum
1. FDA approved Amphastar's ANDA for Iron Sucrose Injection, boosting market entry. 2. Potential sales of $80 million to $100 million by targeting Venofer's market share. 3. Analyst upgrade to Buy rating with a target price of $36 supports growth. 4. Deal with Nanjing Anji may enhance future revenue from proprietary peptides. 5. AMPH shares rose by over 9% following FDA approval and analyst upgrade.